Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Innovation Crisis? First-In-Class Drug Approvals Stable For Almost 25 Years, FDA Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

An FDA study evaluating NMEs by level of innovation finds level first-in-class approvals to be consistent, and approvals after the study period reinforce “encouraging” findings. Analysis says new metric should be basis for assessment of programs created by FDASIA to speed development of innovative products.

You may also be interested in...



Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals

As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.

Changing Face Of ‘Me Too’ Drugs On Display In 2014 NME Approvals

As the era of the primary care blockbusters waned, pharma R&D shifted toward less price-sensitive specialty fields. Now successful specialty drug development is producing its own sort of follow-on agents, and payers are pushing back. Even oncology is not immune.

Medical Advances Account For Half Of CDER 2013 NMEs

Fourteen first-in-class and advance-in-class NMEs were approved by CDER in 2013, accounting for 52% of new drug approvals. The most innovative drugs represent a lower share of approvals in 2013 compared with recent years, but the total of nine first-in-class NMEs is in line with the 25-year average.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel